EasyM has been demonstrated to be effective in blind clinical trials. Hundreds of patients have been evaluated, and thousands of samples examined in collaboration with dozens of researchers around the world. Please find links below to explore the details of the method, and the results of trials demonstrating its sensitivity and effectiveness.
A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM) Mariya Liyasova, Zac McDonald, Paul Taylor; Kathleen Gorospe, Xin Xu, Chenyu Yao, Qixin Liu, Liqiang Yang, Eshetu G. Atenafu, Giovanni Piza; Bin Ma; Donna Reece; Suzanne Trudel. Clin Cancer Res (2021) 27 (18):5028–5037. https://doi.org/10.1158/1078-0432.CCR-21-0649
Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients
Zac McDonald, Paul Taylor, Mariya Liyasova, Qixin Liu, and Bin Ma. Journal of Proteome Research 2021 20 (8), 4176-4185 DOI: 10.1021/acs.jproteome.0c01022
Clonotypic Mass Spectrometry with EasyM Assay for Detection of Measurable Residual Disease in Multiple Myeloma
Michael J Slade, MD, MS Abir Khalid, PhD2*, Mark A Fiala, PhD3*, Mariya Liyasova, PhD4*, Mark A Zaydman, MD, PhD5*, Zac McDonald, PhD4*, Julie M Fortier, PhD3*, Sarah Kelley6*, Zachary D. Crees, MD7, Mark A. Schroeder, MD8, Keith E Stockerl-Goldstein, MD3, Liqiang Yang, PhD4* and Ravi Vij, MD, MBBS8, American Society of Hematology Annual Meeting and Expo 2023, Poster 1908, Session 652
Comparison with other tests: In a small scale clinical trial, we demonstrated high correlation between EasyM and a leading NGS-based assay, but with higher sensitivity – e.g. in several cases where the NGS result was MRD negative, we were still able to detect M-protein.